Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study

Bibliographic Details
Title: Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study
Authors: Pazdera, Ladislav i, Rizova, Yuliya i, Azulay, Jean-Philippe j, Danaila, Teodor j, Defebvre, Luc j, Durif, Franck j, Roullet-Solignac, Isabelle j, Ebersbach, Georg k, Kassubek, Jan-Rainer k, Muhlack, Siegfried k, Schwarz, Johannes k, Arkadir, David l, Djaldetti, Ruth l, Hassin-Baer, Sharon l, Milo, Ron l, Yahalom, Gilad l, Antonini, Angelo m, Bonuccelli, Ubaldo m, Gasparoli, Elisabetta m, Onofrj, Marco m, Krawczyk, Malgorzata n, Rejdak, Konrad n, Rudzińska, Monika n, Aldred, Jason o, Aralu, Cletus o, Bhatia, Perminder o, Biton, Victor o, Cutler, Barry o, Flitman, Stephen o, Gil, Ramon o, Ginsberg, Paul o, Greenberg, Jeffrey o, Hauser, Robert A. o, Isa, Arnaldo o, Isaacson, Stuart o, Klepitskaya, Olga o, Klos, Kevin o, Kumar, Rajeev o, Leehey, Maureen o, LeWitt, Peter o, Patel, Neepa o, Safirstein, Beth o, Savitt, Joseph o, Struck, Lynn o, Taylor, Danette o, Thomas, Karen o, Truong, Daniel o, Vasquez, Alberto o, Ellenbogen, Aaron L. a, ⁎, Poewe, Werner b, Espay, Alberto J. c, Simuni, Tanya d, Gurevich, Tanya e, Yardeni, Tami f, Lopes, Nelson f, Sasson, Nissim f, Case, Ryan g, Stocchi, Fabrizio h
Source: In Parkinsonism and Related Disorders March 2025 132
Database: ScienceDirect
More Details
ISSN:13538020
DOI:10.1016/j.parkreldis.2025.107293
Published in:Parkinsonism and Related Disorders
Language:English